Risk of tuberculosis following HIV seroconversion in high-income countries

Thorax

Volumn 68, Issue 3, 2013, Pages 207-213

  Lodi, Sara ^a,b   Del Amo, Julia ^b   Monforte, Antonella D'Arminio ^c   Abgrall, Sophie ^d   Sabin, Caroline ^e   Morrison, Charles ^f   Furrer, Hansjakob ^g   Muga, Roberto ^h   Porter, Kholoud ^a   Girardi, Enrico ⁱ  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF MILAN   (Italy)

^d INSERM   (France)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f FAMILY HEALTH INTERNATIONAL   (United States)

^g UNIVERSITY OF BERN   (Switzerland)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ARTICLE; BONE MARROW BIOPSY; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DISEASE ASSOCIATION; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INCOME; INFECTION RISK; LUNG TUBERCULOSIS; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; PLEURA FLUID; PRIORITY JOURNAL; SEROCONVERSION; SPUTUM ANALYSIS; TRACHEOBRONCHIAL TOILET; TUBERCULOSIS;

EID: 84873707060     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-201740     Document Type: Article

References (28)

1. Girardi E, Antonucci G, Vanacore P., et al GISTA-SIMIT Study Group. Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy. Eur Respir J 2004; 24: 11-17.
2. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19: 2109-16.
3. CASCADE Collaboration. Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol 2002; 31: 951-8.
4. Lawn SD, Myer L, Edwards D., et al Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009; 23: 1717-25.
5. The Antiretroviral Therapy (ART) Cohort Collaboration. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006; 368: 451-8.
6. Abgrall S, Del Giudice P, Melica G, et al HDH-ANRS CO4. HIV-associated tuberculosis and immigration in a high-income country: incidence trends and risk factors in recent years. AIDS 2010; 24: 763-71.
7. Staehelin C, Rickenbach M, Low N., et al Migrants from sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival. AIDS 2003; 17: 2237-44.
8. Grant AD, Bansi L, Ainsworth J., et al United Kingdom Collaborative HIV Cohort Study Group. Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? AIDS 2009; 23: 2507-15.
9. Manabe YC, Breen R, Perti T., et al Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis 2009; 199: 437-44.
10. HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 561-2.
11. Elzi L, Schlegel M, Weber R., et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007; 44: 94-102.
12. World Health Organization. WHO Three 'I's meeting: intensified case finding, isoniazid preventive therapy and TB infection control for people living with HIV. Report of a joint WHO HIV/AIDS and TB Department meeting, 2-4 April 2008, Geneva, Switzerland. http://www.who.int/hiv/pub/tb/3is-mreport/en/index. html (accessed 18 Aug 2011).
13. CASCADE Collaboration in EuroCoord. http://www.cascade-collaboration.org. (accessed 9 February 2012).
14. European Centre for the Epidemiological Monitoring of AIDS. 1993 revision of the European AIDS surveillance case definition. AIDS Surveill Eur Q Rep 1993; (37): 23-8.
15. Lodi S, Guiguet M, Costagliola D., et al Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J Natl Cancer Inst 2010; 102: 784-92.
16. van Asten L., Langendam M, Zangerle R., et al Tuberculosis risk varies with the duration of HIV infection: a prospective study of European drug users with known date of HIV seroconversion. AIDS 2003; 17: 1201-8.
17. Muga R, Ferreros I, Langohr K., et al Spanish Multicenter Study Group of Seroconverters (GEMES). Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. AIDS 2007; 21: 2521-7.
18. Sonnenberg P, Glnn JR, Fielding K, et al How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005; 191: 150-8.
19. Diedrich CR, Mattila JT, Klein E, et al Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. PLoS One 2010; 5: e9611.
20. Geldmacher C, Ngwenyama N, Schuetz A., et al Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4T cells after HIV-1 infection. J Exp Med 2010; 207: 2869-81.
21. Lawn SD, Bekker LG, Wood R. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS 2005; 19: 1113-24.
22. Mocroft A, Reiss P, Kirk O., et al on behalf of COHERE. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count cells/microL? Clin Infect Dis 2010; 51: 611-19.
23. World Health Organization. Global tuberculosis control 2011. http://www.who.int/tb/publications/global-report/2011/gtbr11-full.pdf (accessed online 11 Oct 2011).
24. Sterling TR, Lau B, Zhang J., et al (for NA-ACCORD/IeDEA). Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. Journal of Infectious Diseases 2011; 204: 893-901.
25. Müller M., Wandel S, Colebunders R., et al Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 251-61.
26. HIV CAUSAL Collaboration. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clin Infect Dis 2012; 54: 1364-72.
27. Lawn SD, Kranzer K, Edwards D.J., et al Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS 2010; 24: 1323-8.
28. Akolo C, Adetifa I, Shepperd S., et al Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; (1): CD000171.